A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.

Donald E Tsai; Selina M Luger; Charalambos Andreadis; Dan T Vogl; Allison Kemner; Melissa Potuzak; Ami Goradia; Alison W Loren; Alexander E Perl; Stephen J Schuster

doi:10.1158/1078-0432.CCR-07-5185

A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.

Identifier:nobleid.org/w1/20260515/0CD28938

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/0CD28938.svg?ark=w1%2F20260515%2F0CD28938)](https://nobleid.org/work/w1/20260515/0CD28938)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Donald E Tsai

Selina M Luger

Charalambos Andreadis

Claim authorship of this work

A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.

Identifier:nobleid.org/w1/20260515/0CD28938

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/0CD28938.svg?ark=w1%2F20260515%2F0CD28938)](https://nobleid.org/work/w1/20260515/0CD28938)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Donald E Tsai

Selina M Luger

Charalambos Andreadis

Claim authorship of this work